Ibio reports in vivo proof of concept for 3 immuno-oncology candidates
Aug. 16, 2023
Ibio Inc. has announced promising in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.